

Oncology Today with Dr Neil Love: Current and Future Role of Molecular Residual Disease Analysis and Its Relevance in Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the GALAXY observational study of patients with localized colorectal cancer (CRC), which of the following biomarkers confers the most unfavorable prognosis for disease-free survival?
 - a. Left-sided tumor location
 - b. Circulating tumor DNA (ctDNA) positivity in the molecular residual disease (MRD) window after surgery
 - c. Microsatellite instability-high status
 - d. Pathological tumor stage N2
2. Which of the following statements best characterizes an outcome from the observational BESPOKE CRC study of patients with pathological Stage II to III CRC who were postoperatively monitored for MRD by ctDNA testing?
 - a. ctDNA-based MRD testing is not predictive of the benefit of adjuvant chemotherapy
 - b. ctDNA-based MRD testing is predictive of the benefit of adjuvant chemotherapy
 - c. ctDNA-based MRD testing is not predictive of the benefit of adjuvant immunotherapy
 - d. ctDNA-based MRD testing is predictive of the benefit of adjuvant immunotherapy
3. Which of the following outcomes best represents results of the Phase III CALGB/SWOG-80702 trial evaluating the addition of celecoxib versus placebo to standard adjuvant therapy for patients with Stage III colon cancer?
 - a. No significant disease-free survival (DFS) improvement among patients with and without detectable ctDNA
 - b. Significant DFS improvement among patients with detectable ctDNA
 - c. Significant DFS improvement among patients with and without detectable ctDNA
4. In the GALAXY trial, the association between ctDNA positivity during the MRD window or at any time after surgery and the site of disease recurrence is best characterized by which of the following statements?
 - a. Lung metastases are the most common site of recurrence for patients with a positive ctDNA result
 - b. Peritoneal metastases are the most common site of recurrence for patients with a positive ctDNA result
 - c. Liver metastases are the most common site of recurrence for patients with a positive ctDNA result
5. The Phase III placebo-controlled ALASCCA trial evaluated which of the following adjuvant therapies for patients with PI3K-altered localized CRC?
 - a. Low-dose atorvastatin
 - b. Low-dose aspirin
 - c. Low-dose escitalopram